Y-box结合蛋白-1和细胞周期蛋白D1在前列腺癌中的表达及其临床意义
|
摘要
目的探讨Y-box结合蛋白-1(YB-1)和细胞周期蛋白D1(cyclin D1)在前列腺组织中的表达水平及临床意义。方法收集122例前列腺癌标本及60例良性前列腺增生标本,采用免疫组化S-P法检测YB-1和cyclin D1蛋白的表达水平;并分析两者与前列腺癌患者临床病理参数的相关性。结果前列腺癌组织中YB-1、cyclin D1表达的阳性率均高于前列腺增生组织,差异有统计学意义(P<0.05)。前列腺癌组织中YB-1、cyclin D1的表达与PSA水平、临床分期、Gleason评分有关,差异有统计学意义(P<0.05)。前列腺癌组织中YB-1与cyclin D1的表达呈正相关(r=0.459,P<0.05)。结论前列腺癌组织中YB-1、cyclin D1高表达,且与PSA水平、临床分期、Gleason评分有关。
Objective To investigate the expressions of Y-Box binding protein-1 and Cyclin D1 in the prostate cancer and clinical signficance. Methods Immunohistochemical S-P mathod was used to detect the expressions of YB-1 and cyclin D1 in the 122 cases of prostate cancer and 60 cases of benign prostate hyperplasia( BPH). The relationship between YB-1,cyclin D1 and clinicopathlogical parameters were analyzed. Results The positive rates of YB-1 and cyclin D1 in the prostate cancer were significantly higher than those in the BPH( P < 0. 05). The expressions of YB-1 and cyclin D1 in the prostate cancer were related with PSA,Gleason score and clinical tumor stage,the difference was statistically significant( P < 0. 05). In the prostate cancer,the expression of YB-1 was positively related with cyclin D1( r = 0. 459,P < 0. 05). Conclusion The expressions of YB-1 and cyclin D1 are higher in the prostate cancer than BPH,and are related with PSA,Gleason score and clinical tumor stage.
Objective To investigate the expressions of Y-Box binding protein-1 and Cyclin D1 in the prostate cancer and clinical signficance. Methods Immunohistochemical S-P mathod was used to detect the expressions of YB-1 and cyclin D1 in the 122 cases of prostate cancer and 60 cases of benign prostate hyperplasia( BPH). The relationship between YB-1,cyclin D1 and clinicopathlogical parameters were analyzed. Results The positive rates of YB-1 and cyclin D1 in the prostate cancer were significantly higher than those in the BPH( P < 0. 05). The expressions of YB-1 and cyclin D1 in the prostate cancer were related with PSA,Gleason score and clinical tumor stage,the difference was statistically significant( P < 0. 05). In the prostate cancer,the expression of YB-1 was positively related with cyclin D1( r = 0. 459,P < 0. 05). Conclusion The expressions of YB-1 and cyclin D1 are higher in the prostate cancer than BPH,and are related with PSA,Gleason score and clinical tumor stage.
引文
[1]韩苏军,张思维,陈万青,等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334.
[2]Eliseeva I A,Kim E R,Guryanov S G,et al.Y-box-binding protein1(YB-1)and its functions[J].Biochemistry(Mosc),2011,76(13):1402-1433.
[3]Lyabin D N,Eliseeva I A,Ovchinnikov L P.YB-1 protein:functions and regulation[J].Wiley Interdiscip Rev RNA,2014,5(1):95-110.
[4]Sun R,Jiang B,Qi H,et al.SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2[J].Cell Death Dis,2015,6:e1990.
[5]Kolk A,Jubitz N,Mengele K,et al.Expression of Y-box-binding protein YB-1 allows stratification into long-and short-term survivors of head and neck cancer patients[J].Br J Cancer,2011,105(12):1864-1873.
[6]Shibahara K,Sugio K,Osaki T,et al.Nuclear expression of the Y-box binding protein,YB-1,as a novel marker of disease progression in nonsmall cell lung cancer[J].Clin Cancer Res,2001,7(10):3151-3155.
[7]Gessner C,Woischwill C,Schumacher A,et al.Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer[J].Eur Respir J,2004,23(1):14-19.
[8]Heumann A,Kaya O,Burdelski C,et al.Up regulation and nuclear translocation of Y-box binding protein 1(YB-1)is linked to poor prognosis in ERG-negative prostate cancer[J].Sci Rep,2017,7(1):2056.
[9]Jung K H,Kim J K,Noh J H,et al.Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma[J].J Cell Biochem,2010,110(3):687-696.
[2]Eliseeva I A,Kim E R,Guryanov S G,et al.Y-box-binding protein1(YB-1)and its functions[J].Biochemistry(Mosc),2011,76(13):1402-1433.
[3]Lyabin D N,Eliseeva I A,Ovchinnikov L P.YB-1 protein:functions and regulation[J].Wiley Interdiscip Rev RNA,2014,5(1):95-110.
[4]Sun R,Jiang B,Qi H,et al.SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2[J].Cell Death Dis,2015,6:e1990.
[5]Kolk A,Jubitz N,Mengele K,et al.Expression of Y-box-binding protein YB-1 allows stratification into long-and short-term survivors of head and neck cancer patients[J].Br J Cancer,2011,105(12):1864-1873.
[6]Shibahara K,Sugio K,Osaki T,et al.Nuclear expression of the Y-box binding protein,YB-1,as a novel marker of disease progression in nonsmall cell lung cancer[J].Clin Cancer Res,2001,7(10):3151-3155.
[7]Gessner C,Woischwill C,Schumacher A,et al.Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer[J].Eur Respir J,2004,23(1):14-19.
[8]Heumann A,Kaya O,Burdelski C,et al.Up regulation and nuclear translocation of Y-box binding protein 1(YB-1)is linked to poor prognosis in ERG-negative prostate cancer[J].Sci Rep,2017,7(1):2056.
[9]Jung K H,Kim J K,Noh J H,et al.Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma[J].J Cell Biochem,2010,110(3):687-696.